Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies

C. M. Camaggi; E. Strocchi; A. Martoni; C. Zamagni; N. Cacciari; G. Robustelli della Cuna; L. Pavesi; M. Tedeschi; A. Silva; F. Pannuti

doi:10.1007/BF00689055

Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies

C. M. Camaggi, E. Strocchi, A. Martoni, C. Zamagni, N. Cacciari, G. Robustelli della Cuna, L. Pavesi, M. Tedeschi, A. Silva, F. Pannuti

Istituti Clinici Scientifici Maugeri Spa – Società Benefit

Research output: Contribution to journal › Article › peer-review

Abstract

The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets", was investigated in a single-dose, open-label, balanced-for-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.

Original language	English
Pages (from-to)	356-359
Number of pages	4
Journal	Cancer Chemotherapy and Pharmacology
Volume	36
Issue number	4
DOIs	https://doi.org/10.1007/BF00689055
Publication status	Published - Jul 1995

Keywords

Bioequivalence
Megestrol acetate
Pharmacokinetics

ASJC Scopus subject areas

Pharmacology
Oncology
Cancer Research

Access to Document

10.1007/BF00689055

Fingerprint Dive into the research topics of 'Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies'. Together they form a unique fingerprint.

Cite this

Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies. / Camaggi, C. M.; Strocchi, E.; Martoni, A.; Zamagni, C.; Cacciari, N.; Robustelli della Cuna, G.; Pavesi, L.; Tedeschi, M.; Silva, A.; Pannuti, F.

In: Cancer Chemotherapy and Pharmacology, Vol. 36, No. 4, 07.1995, p. 356-359.

Research output: Contribution to journal › Article › peer-review

@article{931dd2e8f63b471c8c2312b9d44f1907,

title = "Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies",

abstract = "The bioequivalence of two megestrol acetate formulations, 160-mg {"}tablets{"} and 160-mg {"}sachets{"}, was investigated in a single-dose, open-label, balanced-for-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.",

keywords = "Bioequivalence, Megestrol acetate, Pharmacokinetics",

author = "Camaggi, {C. M.} and E. Strocchi and A. Martoni and C. Zamagni and N. Cacciari and {Robustelli della Cuna}, G. and L. Pavesi and M. Tedeschi and A. Silva and F. Pannuti",

year = "1995",

month = jul,

doi = "10.1007/BF00689055",

language = "English",

volume = "36",

pages = "356--359",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer Verlag",

number = "4",

}

TY - JOUR

T1 - Pharmacokinetic evaluation of two different formulations of megestrol acetate in patients with advanced malignancies

AU - Camaggi, C. M.

AU - Strocchi, E.

AU - Martoni, A.

AU - Zamagni, C.

AU - Cacciari, N.

AU - Robustelli della Cuna, G.

AU - Pavesi, L.

AU - Tedeschi, M.

AU - Silva, A.

AU - Pannuti, F.

PY - 1995/7

Y1 - 1995/7

N2 - The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets", was investigated in a single-dose, open-label, balanced-for-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.

AB - The bioequivalence of two megestrol acetate formulations, 160-mg "tablets" and 160-mg "sachets", was investigated in a single-dose, open-label, balanced-for-sequence cross-over study involving 12 advanced-cancer patients. The observed plasma megestrol-acetate time course obtained with both formulations was consistent with the literature data. The main source of variability in the pharmacokinetic parameters was intersubject variability; drug formulation played only a minor (and nonsignificant) role. The width of the 90% confidence interval of the areaunder-the-curve (AUC) ratio (sachets: tablets) computed according to Schuirmann (0.9-1.4) was mainly due to the presence of a single outlier, showing an AUC ratio of 2.7. The trend to higher bioavailability of the new formulation was not significant, especially as compared with the doseresponse data reported in the literature.

KW - Bioequivalence

KW - Megestrol acetate

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0029019018&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029019018&partnerID=8YFLogxK

U2 - 10.1007/BF00689055

DO - 10.1007/BF00689055

M3 - Article

C2 - 7628056

AN - SCOPUS:0029019018

VL - 36

SP - 356

EP - 359

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 4

ER -